IP Library › Granted Patent US 6,984,729
Granted Patent B1
US 6,984,729 · App. 08/901,612 · Granted Jan 10, 2006

Oligonucleotides specific for hepatitis B virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,984,729
App. No.
08/901,612
Granted
Jan 10, 2006
Kind
B1
Abstract

The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.

Claims (43)

1. A synthetic oligonucleotide selected from the group consisting of SEQ ID NOS: 7–10, 12–19,45, and 58–65, which oligonucleotide inhibits HBV replication.

2. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 7 or 58.

3. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 8 or 59.

4. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 9, 60, or 61.

5. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 10.

6. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 12.

7. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 13.

8. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 14.

9. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 15, 62, or 63.

10. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 16 or 64.

11. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 17.

12. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 18.

13. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO: 19 or 65.

14. The synthetic oligonucleotide of claim 1 , wherein the oligonucleotide is SEQ ID NO:45.

15. The synthetic oligonucleotide of claim 1 which is modified.

16. The oligonucleotide of claim 15 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

17. The oligonucleotide of claim 16 comprising at least one phosphorothioate internucleotide linkage.

18. The oligonucleotide of claim 17 comprising one phosphorothioate internucleotide linkage.

19. The oligonucleotide of claim 1 which comprises at least one deoxyribonucleotide.

20. The oligonucleotide of claim 1 which comprises at least one ribonucleotide.

21. The oligonucleotide of claim 19 which comprises at least one ribonucleotide.

22. The oligonucleotide of claim 20 comprising at least one 2′-O-methyl nucleotide.

23. A kit comprising at least one oligonucleotide of claim 1 .

24. A kit comprising at least two oligonucleotides of claim 1 .

25. A composition comprising at least one oligonucleotide of claim 1 admixed with a pharmaceutically acceptable carrier.

26. The synthetic oligonucleotide of claim 9 which is modified.

27. The oligonucleotide of claim 26 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

28. The oligonucleotide of claim 27 comprising at least one phosphorothioate internucleotide linkage.

29. The oligonucleotide of claim 28 comprising one phosphorothioate internucleotide linkage.

30. The oligonucleotide of claim 10 which comprises at least one deoxyribonucleotide.

31. The oligonucleotide of claim 10 which comprises at least one ribonucleotide.

32. The oligonucleotide of claim 30 which comprises at least one ribonucleotide.

33. The oligonucleotide of claim 31 comprising at least one 2′-O-methyl nucleotide.

34. A kit comprising at least the oligonucleotide of claim 9 .

35. The synthetic oligonucleotide of claim 12 which is modified.

36. The oligonucleotide of claim 35 wherein the modification comprises at lest one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

37. The oligonucleotide of claim 36 comprising at least one phosphorothioate internucleotide linkage.

38. The oligonucleotide of claim 35 comprising phosphorothioate internucleotide linkages.

39. The oligonucleotide of claim 38 which comprises at least one deoxyribonucleotide.

40. The oligonucleotide of claim 39 which comprises at least one ribonucleotide.

41. The oligonucleotide of claim 12 which comprises at least one ribonucleotide.

42. The oligonucleotide of claim 40 comprising at least one 2′-O-methyl nucleotide.

43. A kit comprising at least the oligonucleotide of claim 12 .

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2005
From: HYBRIDON, INC
To: IDERA PHARMACEUTICALS, INC
Reel/Frame 017240/0865 →
SECURITY INTEREST Recorded Jan 29, 1998
From: HYBRIDON, INC.
To: SILICON VALLEY BANK
Reel/Frame 008933/0844 →